Real-Time Lung Cancer Detection Now Possible with New Blood Test
Published: Dec 22, 2025
Updated: Dec 22, 2025
Published: Dec 22, 2025
Updated: Dec 22, 2025
A new blood test developed by UK researchers can detect lung cancer in real time, potentially revolutionising treatment monitoring and early diagnosis. This is an important advancement in the diagnosis of cancer.
The study presents a novel method for identifying a single lung cancer cell in the blood. This development may enhance patient survival rates and drastically cut down on diagnostic delays.
This innovative method analyses blood samples using cutting-edge infrared technology, in contrast to conventional methods that are frequently invasive, complicated, or time-consuming. Each cancer cell has its own chemical signature. Researchers may quickly identify circulating tumor cells (CTCs) by scanning blood with a strong infrared beam and combining the data with computer-based analysis. These cells leave tumors and enter the bloodstream.
CTCs are important markers of the development of cancer, the effectiveness of treatment, and the spread of the illness to other organs.
Current methods for detecting circulating tumour cells can be costly and unreliable, particularly because cancer cells often alter their properties as they circulate in the blood. This new approach is simpler, faster, and more affordable, using standard laboratory tools already available in most pathology labs.
According to the researchers, this technique has the potential to:
A scientific journal has published the results, and larger patient trials are planned to advance a fully automated, rapid blood test for routine cancer care.
MediGence makes it easier for patients to access the most recent developments in oncology at top hospitals across the globe as medical science continues to make incredible progress in cancer detection and treatment. From early diagnostics to advanced treatment planning, MediGence connects patients with trusted cancer specialists, modern healthcare facilities, and personalised medical solutions.
MediGence is dedicated to bridging the gap between groundbreaking research and patient access, ensuring that high-quality care is accessible when it counts most, even while advances like real-time blood tests shape the future of cancer care.
Alvina Hasan is a dedicated medical researcher and scientific writer with a strong foundation in the pharmaceutical sciences. She holds a B.Pharm from Jamia Hamdard University and an M.Pharm in Quality Assurance from DIPSAR University. With deep medical expertise and a strong interest in healthcare communication, she focuses on transforming complex clinical and scientific information into clear, engaging, and easy-to-understand narratives. She develops insightful healthcare articles and research-driven pieces designed to support both medical professionals and patients, helping bridge the gap between advanced medical knowledge and practical understanding.
Dr. Vishwas Kaushik, an accomplished Belgorod State University graduate with an MBBS, is known for his impactful contributions to healthcare. Driven by a passion for global well-being, he seamlessly led domestic operations at VMV Group of Companies and orchestrated success at Clear Medi Cancer Centre. His adept team management and operational skills have positioned him as a luminary in healthcare tourism, shaping a future where compassionate, world-class medical care knows no boundaries.
Delhi, India
Istanbul, Turkey
Istanbul, Turkey
Istanbul, Turkey
Active
.png)
.png)
.jpg)
